RDHL · RedHill Biopharma Ltd. · Documents
Market Cap
$3.75M
Shares
8.89M
Volume · Oct 23
86.95K
Avg daily vol (3M)
2.04M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 6-K | RedHill Biopharma Ltd. regained ex-North America rights to RHB-102 through a mutual agreement with Hyloris Pharmaceuticals SA, which effectively terminated the License Agreement on October 15, 2026 and triggered a one-time $200,000 break-up fee. | 2026-10-21 | — | |
| 6-K | RedHill Biopharma announced its partner the University of Oklahoma received a five-year, $2.9 million NCI grant to trial RedHill's opaganib combined with CAR T-cell therapy in ultra-high-risk multiple myeloma, including a Phase 1b enrolling up to 18 patients and a Phase 2 enrolling up to 21. | 2026-10-19 | — | |
| 6-K | RedHill Biopharma Ltd. increased the maximum aggregate offering amount to $2,587,409 for American Depositary Shares, each representing ten thousand (10,000) ordinary shares, sold from time to time under its February 3, 2025 At The Market Offering Agreement with H.C. Wainwright & Co., LLC. | 2026-10-13 | — | |
| 6-K | RedHill Biopharma Ltd. received an additional 180 calendar day period, until April 5, 2027, to regain Nasdaq compliance with the $1.00 per share minimum bid price requirement; the ADSs remain listed and trading under “RDHL.” | 2026-10-07 | — | |
| 6-K | — | 2026-09-30 | — | |
| 6-K | — | 2026-09-30 | 2026-06-30 | |
| 6-K | — | 2026-09-01 | — | |
| 6-K | — | 2026-08-31 | — | |
| 6-K | — | 2026-08-07 | — | |
| 6-K | — | 2026-08-06 | — | |
| 6-K | — | 2026-07-28 | — | |
| F-3 | — | 2026-07-02 | — | |
| 6-K | — | 2026-07-01 | — | |
| 6-K | — | 2026-06-29 | — | |
| 6-K | — | 2026-06-25 | — | |
| 6-K | — | 2026-06-22 | — | |
| 6-K | — | 2026-06-22 | — | |
| 6-K | — | 2026-06-22 | — | |
| 6-K | — | 2026-06-18 | — | |
| 6-K | — | 2026-06-09 | — | |
| 6-K | — | 2026-06-08 | — | |
| 6-K | — | 2026-06-02 | — | |
| 6-K | — | 2026-05-27 | — | |
| 6-K | — | 2026-04-30 | — | |
| 20-F | — | 2026-04-27 | 2025-12-31 | |
| 6-K | — | 2026-04-27 | — | |
| 6-K | — | 2026-04-22 | — | |
| 6-K | — | 2026-04-14 | — | |
| 6-K | — | 2026-03-05 | — | |
| 6-K | — | 2026-02-25 | — | |
| 6-K | — | 2026-01-27 | — | |
| F-1/A | — | 2026-01-22 | — | |
| 6-K | — | 2026-01-22 | — | |
| 6-K | — | 2026-01-05 | — | |
| F-1 | — | 2025-12-31 | — | |
| 6-K | — | 2025-12-31 | — | |
| 6-K | — | 2025-12-23 | — | |
| 6-K | — | 2025-12-15 | — | |
| 6-K | — | 2025-12-01 | — | |
| 6-K | — | 2025-11-26 | — | |
| 6-K | — | 2025-11-04 | — | |
| 6-K | — | 2025-10-22 | — | |
| 6-K | — | 2025-10-21 | — | |
| 6-K | — | 2025-10-20 | — | |
| 6-K | — | 2025-10-06 | — | |
| 6-K | — | 2025-09-29 | — | |
| 6-K/A | — | 2025-09-05 | 2025-06-30 | |
| 6-K | — | 2025-09-05 | 2025-06-30 | |
| 6-K | — | 2025-08-20 | — | |
| 6-K | — | 2025-08-18 | — |
Showing 1–50 of 382 filings